MedTrace Logo

Prognosis of METTL-14 in Endometrial Carcinoma

NCT06861855 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-09-30

No results posted yet for this study

Summary

1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma.
2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection.
3. To assess correlation of METTL-14 expression with disease free survival and overall survival.

Conditions

Interventions

OTHER

Observation

observation of METTL-14 prognosis

BEHAVIORAL

IHC

IHC of METTL-14

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-27
Primary Completion
2026-08-31
Completion
2026-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06861855 on ClinicalTrials.gov